1-(4-ethylphenoxy)-4-methoxybenzene | 1111089-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-ethylphenoxy)-4-methoxybenzene
• 英文别名: 1-Ethyl-4-(4-methoxyphenoxy)benzene
• CAS: 1111089-35-0
• 化学式: C₁₅H₁₆O₂
• 分子量: 228.291
• InChiKey: ODABEDBPXGKORG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-乙基苯酚 、 4-甲氧基苯硼酸 在 吡啶 、 copper diacetate 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以70%的产率得到1-(4-ethylphenoxy)-4-methoxybenzene
  参考文献：
  名称：

  Copper-mediated N- and O-arylations with arylboronic acids in a continuous flow microreactor: a new avenue for efficient scalability

  摘要：

  A continuous flow procedure has been elaborated for the copper(II)-mediated N- and O-arylation of a range of compounds with arylboronic acids using a commercial microreactor setup. The compounds could be continuously generated in good yields paving the way for efficient scalability. (C) 2008 Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2008.09.159

文献信息

• [EN] SMALL MOLECULE ANTAGONISTS OF SUMO RELATED MODIFICATION OF CRMP2 AND USES THEREOF<br/>[FR] ANTAGONISTES À PETITES MOLÉCULES DE LA MODIFICATION LIÉE AU SUMO DE CRMP2 ET LEURS UTILISATIONS
  申请人：UNIV ARIZONA

  公开号：WO2018144900A1

  公开（公告）日：2018-08-09

  This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a piperidinyl-benzoimidazole structure which function as antagonists of small ubiquitin like modifier (SUMO) related modification (SUMOylation) of collapsin response mediator protein 2 (CRMP2), and their use as therapeutics for the treatment of voltage gated sodium channel 1.7 (Nav1.7) related itch, anosmia, migraine event, and/or pain (e.g., neuropathic pain).

  这项发明属于药物化学领域。具体来说，该发明涉及一类具有哌啶基苯并咪唑结构的小分子，其作为小泛素样修饰物（SUMO）相关修饰（SUMOylation）的抗体，用作治疗与电压门控钠通道1.7（Nav1.7）相关的瘙痒、嗅觉丧失、偏头痛事件和/或疼痛（例如，神经病性疼痛）的治疗药物。
• Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
  申请人：Cheng T. Peter

  公开号：US20070015797A1

  公开（公告）日：2007-01-18

  Compounds are provided which have the structure wherein Q is C or N, A is O or S, Z is O or a bond, X is CH or N and R 1 , R 2 , R 2a , R 2b , R 2c , R 3 , Y, x, m, and n are as defined herein, which compounds are useful as antidiabetic, hypolipidemic, and antiobesity agents.

  提供了一些化合物，它们的结构如下：其中Q为C或N，A为O或S，Z为O或键，X为CH或N，R1、R2、R2a、R2b、R2c、R3、Y、x、m和n如此定义，这些化合物可用作抗糖尿病、降脂和抗肥胖药物。
• Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1162194A1

  公开（公告）日：2001-12-12

  The present invention relates to compounds of the formula I, in which R1, R2, R3, R4, R5, R6, A, X, m and n have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of thromboembolic diseases and restenoses. They are reversible inhibitors of the blood clotting enzyme factor VIIa and can in general be applied in conditions in which an undesired activity of factor VIIa is present or for the cure or prevention of which an inhibition of factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

  本发明涉及式 I 的化合物、 其中 R1、R2、R3、R4、R5、R6、A、X、m 和 n 具有权利要求中所述的含义。式 I 的化合物是具有重要药理活性的化合物。它们具有很强的抗血栓作用，适用于血栓栓塞性疾病和再狭窄的治疗和预防。它们是凝血酶 VIIa 因子的可逆抑制剂，一般可用于存在 VIIa 因子不良活性的情况，或用于抑制 VIIa 因子的治疗或预防。此外，本发明还涉及式 I 化合物的制备工艺、其用途（尤其是作为药物的活性成分）以及由其组成的药物制剂。
• FACTOR VIIA INHIBITORY (THIO)UREA DERIVATIVES, THEIR PREPARATION AND THEIR USE
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1299354A2

  公开（公告）日：2003-04-09
• POLYMER ELECTROLYTE COMPOSITION, ELECTROLYTE MEMBRANE, MEMBRANE-ELECTRODE ASSEMBLY AND FUEL CELL
  申请人：LG Cham, Ltd.

  公开号：US20140363754A1

  公开（公告）日：2014-12-11

  Provided are a polymer electrolyte composition, an electrolyte membrane, a membrane electrolyte assembly, and a fuel cell. The polymer electrolyte composition according to an exemplary embodiment of this application includes a first solvent, a second solvent which is different from the first solvent, and a polymer which is reacted with the first solvent and the second solvent, in which the polymer includes a functional group which reacts with the first solvent by a first reaction energy and with the second solvent by a second reaction energy, and the second reaction energy is smaller than the first reaction energy.